Duyuru • May 14
WON TECH Co.,Ltd. announced that it expects to receive KRW 75 billion in funding WON TECH Co.,Ltd. announced a private placement to issue series 3 bearer-type unsecured private placement convertible bonds for gross proceeds of KRW 75,000,000,000 on May 14, 2026. The transaction includes participation from new investors, Beauty Device 2026 PEF for KRW of 40,000,000,000 and PACM KOSDAQ Venture No. 1 General Private Equity Investment Trust, a fund advised by NH Investment & Securities Co., Ltd for KRW 35,000,000,000. The bonds have zero coupon rate and zero yield to maturity rate. The bonds will mature on May 22, 2031. The bonds will be 100% converted into 9,068,923 common shares at a fixed conversion price of KRW 8,270 per share. The conversion period is from May 22, 2027 to April 22, 2031. The payment date of the transaction is May 22, 2026. The transaction has been approved by the board of directors of the company. The securities are subject to prohibition of conversion, division, and merger for one year from the bond issuance date. Valuation Update With 7 Day Price Move • May 11
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩8,860, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total returns to shareholders of 15% over the past three years. Major Estimate Revision • Apr 17
Consensus EPS estimates increase by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩185.6m to ₩189.4m. EPS estimate increased from ₩456 to ₩526 per share. Net income forecast to grow 34% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩10,600. Share price rose 6.8% to ₩7,650 over the past week. Price Target Changed • Apr 16
Price target decreased by 8.6% to ₩10,600 Down from ₩11,600, the current price target is an average from 5 analysts. New target price is 40% above last closing price of ₩7,580. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₩526 for next year compared to ₩393 last year. Duyuru • Apr 11
WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares. WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares pursuant to a contract with Samsung Securities. The purpose of the program is to stabilize stock price, employee compensation and enhancement of shareholder value. The program will expire on October 10, 2026. As of April 9, 2026, the company had 741,749 treasury stock within the scope of dividend and 3,793 treasury stock within the scope of other acquisition. Major Estimate Revision • Apr 07
Consensus EPS estimates fall by 25% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from ₩607 to ₩456 per share. Revenue forecast steady at ₩185.6m. Net income forecast to grow 16% next year vs 57% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩11,600 to ₩10,800. Share price was steady at ₩6,650 over the past week. Duyuru • Mar 10
WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026 WON TECH Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩6,600, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,278 per share. Buy Or Sell Opportunity • Feb 05
Now 23% undervalued Over the last 90 days, the stock has risen 9.4% to ₩8,860. The fair value is estimated to be ₩11,478, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 52% in the next 2 years. Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩10,220, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 117% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,310 per share. Valuation Update With 7 Day Price Move • Jan 02
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩8,250, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,331 per share. Price Target Changed • Nov 20
Price target decreased by 11% to ₩11,200 Down from ₩12,600, the current price target is an average from 5 analysts. New target price is 49% above last closing price of ₩7,520. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₩524 for next year compared to ₩327 last year. Reported Earnings • Nov 14
Third quarter 2025 earnings released: EPS: ₩88.00 (vs ₩54.00 in 3Q 2024) Third quarter 2025 results: EPS: ₩88.00 (up from ₩54.00 in 3Q 2024). Revenue: ₩33.2b (up 24% from 3Q 2024). Net income: ₩7.89b (up 64% from 3Q 2024). Profit margin: 24% (up from 18% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Oct 20
WON TECH Co.,Ltd. (KOSDAQ:A336570) announces an Equity Buyback for KRW 6,000 million worth of its shares. WON TECH Co.,Ltd. (KOSDAQ:A336570) announces a share repurchase program. Under the program, the company will repurchase up to for KRW 6,000 million worth of its shares. The program will expire on April 20, 2026. Buy Or Sell Opportunity • Oct 14
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 29% to ₩8,970. The fair value is estimated to be ₩11,268, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 51% in the next 2 years. Reported Earnings • Aug 16
Second quarter 2025 earnings released: EPS: ₩103 (vs ₩50.00 in 2Q 2024) Second quarter 2025 results: EPS: ₩103 (up from ₩50.00 in 2Q 2024). Revenue: ₩39.8b (up 37% from 2Q 2024). Net income: ₩9.20b (up 108% from 2Q 2024). Profit margin: 23% (up from 15% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Aug 13
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩10,450, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 16x in the Medical Equipment industry in South Korea. Total returns to shareholders of 244% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩11,007 per share. Buy Or Sell Opportunity • Jul 25
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 65% to ₩13,250. The fair value is estimated to be ₩10,991, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 53% in the next 2 years. Buy Or Sell Opportunity • Jun 30
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 65% to ₩11,450. The fair value is estimated to be ₩9,329, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 42% in the next 2 years. Buy Or Sell Opportunity • May 29
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 39% to ₩9,360. The fair value is estimated to be ₩7,788, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 44% in the next 2 years. Reported Earnings • May 18
First quarter 2025 earnings released: EPS: ₩135 (vs ₩67.00 in 1Q 2024) First quarter 2025 results: EPS: ₩135 (up from ₩67.00 in 1Q 2024). Revenue: ₩37.4b (up 66% from 1Q 2024). Net income: ₩11.9b (up 101% from 1Q 2024). Profit margin: 32% (up from 26% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Major Estimate Revision • May 14
Consensus revenue estimates increase by 18% The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩134.6m to ₩159.0m. EPS estimate increased from ₩407 to ₩559 per share. Net income forecast to grow 72% next year vs 36% growth forecast for Medical Equipment industry in South Korea. Consensus price target of ₩7,400 unchanged from last update. Share price rose 10% to ₩9,270 over the past week. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩7,250, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩8,009 per share. Price Target Changed • Mar 25
Price target decreased by 22% to ₩6,167 Down from ₩7,938, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of ₩6,130. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₩389 for next year compared to ₩327 last year. Upcoming Dividend • Mar 21
Upcoming dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 25 April 2025. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.3%). Duyuru • Mar 08
WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025 WON TECH Co.,Ltd., Annual General Meeting, Mar 28, 2025, at 11:00 Tokyo Standard Time. Location: conference room, 64, techno 8-ro, yuseong-gu, daejeon South Korea Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₩5,330, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 43% over the past year. Valuation Update With 7 Day Price Move • Dec 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩4,820, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 48% over the past year. Reported Earnings • Nov 20
Third quarter 2024 earnings released: EPS: ₩54.00 (vs ₩101 in 3Q 2023) Third quarter 2024 results: EPS: ₩54.00 (down from ₩101 in 3Q 2023). Revenue: ₩26.9b (up 1.9% from 3Q 2023). Net income: ₩4.81b (down 45% from 3Q 2023). Profit margin: 18% (down from 33% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in South Korea. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 20% per year. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩4,405, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 66% over the past three years. Price Target Changed • Nov 16
Price target decreased by 9.5% to ₩10,633 Down from ₩11,756, the current price target is an average from 9 analysts. New target price is 119% above last closing price of ₩4,845. Stock is down 40% over the past year. The company is forecast to post earnings per share of ₩318 for next year compared to ₩441 last year. Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩6,670, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 177% over the past three years. Major Estimate Revision • Aug 19
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩147.5m to ₩144.8m. EPS estimate also fell from ₩460 per share to ₩413 per share. Net income forecast to grow 65% next year vs 69% growth forecast for Medical Equipment industry in South Korea. Consensus price target down from ₩12,167 to ₩11,778. Share price fell 12% to ₩5,730 over the past week. Reported Earnings • Aug 15
Second quarter 2024 earnings released: EPS: ₩50.00 (vs ₩102 in 2Q 2023) Second quarter 2024 results: EPS: ₩50.00 (down from ₩102 in 2Q 2023). Revenue: ₩29.0b (down 4.9% from 2Q 2023). Net income: ₩4.42b (down 51% from 2Q 2023). Profit margin: 15% (down from 30% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in South Korea. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩6,770, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years. Major Estimate Revision • May 16
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩161.2m to ₩149.8m. EPS estimate also fell from ₩576 per share to ₩514 per share. Net income forecast to grow 17% next year vs 64% growth forecast for Medical Equipment industry in South Korea. Consensus price target broadly unchanged at ₩13,429. Share price fell 23% to ₩8,600 over the past week. Buy Or Sell Opportunity • May 13
Now 36% undervalued Over the last 90 days, the stock has risen 2.3% to ₩8,380. The fair value is estimated to be ₩13,177, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 178%. For the next 3 years, revenue is forecast to grow by 20% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Buy Or Sell Opportunity • Apr 05
Now 21% undervalued Over the last 90 days, the stock has risen 9.9% to ₩10,280. The fair value is estimated to be ₩12,994, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last year. Earnings per share has grown by 179%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 22% per annum over the same time period. New Risk • Apr 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change). Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩9,720, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 365% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩13,055 per share. Reported Earnings • Mar 21
Full year 2023 earnings released: EPS: ₩441 (vs ₩158 in FY 2022) Full year 2023 results: EPS: ₩441 (up from ₩158 in FY 2022). Revenue: ₩115.6b (up 42% from FY 2022). Net income: ₩38.8b (up 190% from FY 2022). Profit margin: 34% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in South Korea. Buy Or Sell Opportunity • Mar 07
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to ₩7,960. The fair value is estimated to be ₩10,064, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 50% over the last year. Earnings per share has grown by 32%. Revenue is forecast to grow by 66% in 2 years. Earnings are forecast to grow by 72% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩9,210, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 338% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,692 per share. Price Target Changed • Feb 15
Price target decreased by 8.0% to ₩13,500 Down from ₩14,667, the current price target is an average from 6 analysts. New target price is 61% above last closing price of ₩8,400. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₩422 for next year compared to ₩158 last year. New Risk • Nov 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change). Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₩10,000, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 393% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩16,716 per share. Price Target Changed • Nov 17
Price target decreased by 7.2% to ₩15,083 Down from ₩16,250, the current price target is an average from 6 analysts. New target price is 86% above last closing price of ₩8,130. Stock is up 135% over the past year. The company is forecast to post earnings per share of ₩441 for next year compared to ₩158 last year. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩8,750, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 331% over the past three years. Valuation Update With 7 Day Price Move • Sep 21
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩10,920, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 442% over the past three years. New Risk • Aug 20
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Price Target Changed • Aug 17
Price target increased by 19% to ₩15,500 Up from ₩13,000, the current price target is an average from 4 analysts. New target price is 15% above last closing price of ₩13,460. Stock is up 338% over the past year. The company is forecast to post earnings per share of ₩489 for next year compared to ₩158 last year. Valuation Update With 7 Day Price Move • Aug 08
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩12,950, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 548% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩24,595 per share. New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin). Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩10,300, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 414% over the past three years. Reported Earnings • May 17
First quarter 2023 earnings released: EPS: ₩134 (vs ₩45.03 in 1Q 2022) First quarter 2023 results: EPS: ₩134. Revenue: ₩28.5b (up 82% from 1Q 2022). Net income: ₩11.8b (down 4.0% from 1Q 2022). Profit margin: 41% (down from 78% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Medical Equipment industry in South Korea. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩7,770, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩6,330, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 219% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩5,116 per share.